Cleveland Clinic Journal of MedicineDeep Cellular Immune Profiling of Psoriatic Arthritis Linked to Imaging Phenotypes and Targeted Therapy Response

The presentation on immune cell profiling could lead to vast advancements in psoriatic arthritis treatment.

A recent study presented at the ACR Convergence 2023 by Dr. Lihi Eder and her team has shed light on the potential of immune cell profiling in managing psoriatic arthritis (PsA). The study suggests that understanding the immune cell phenotypes could help in risk stratification of patients and identifying those who might be more challenging to treat.

Key Points:

• The study used mass cytometry on whole blood to characterize immune cell populations.
• CD4+ memory and Th1 cells were associated with severe synovitis, enthesitis, and poor response to advanced therapies.
• γδT cells and CD8+ naive cells correlated with a milder disease phenotype and improved response to treatment.
• Three distinct immune cell profiles were identified, each associated with different levels of inflammation, patient age, and response to treatment.
• The study suggests that immune cell profiling could potentially inform the selection of targeted disease-modifying anti-rheumatic drugs.

Such patients may benefit from earlier and more intense regimens, and possibly from combination therapy.
– Dr. Lihi Eder, Associate Professor of Medicine and Canada Research Chair in Inflammatory Rheumatic Diseases at the University of Toronto

More on Psoriatic Arthritis